Citation: Liu Z (2023) Pharmacokinetic Assessment of Intranasal Fluticasone Exploring Bioavailability and Absorption Patterns. J Pharmacokinet Exp Ther 7: 190.

(PAR). [illegible] S [illegible] (SAR) [illegible] 4. [illegible] C [illegible] SAR S [illegible] AR [illegible] I [illegible]

[illegible] (- [illegible]

I [illegible] (AOM) [illegible] (RI) [illegible] P [illegible] AOM [illegible] T [illegible] .6 [illegible] AOM, [illegible] AOM. [illegible] AOM [illegible] I [illegible] ([illegible] TNF) [illegible] A [illegible] AOM [illegible] E [illegible] RI [illegible] AOM 3 4 [illegible] AOM. S [illegible] RI [illegible] AOM, [illegible] AOM [illegible] D [illegible] (FP) [illegible] RI [illegible] AOM [illegible] I [illegible] RI [illegible] FP [illegible]

[illegible] K [illegible] 4 [illegible] RI [illegible] 48 [illegible] D [illegible]

AOM, [illegible] 91 (30%) [illegible] 301 [illegible] D [illegible]

[illegible]

229E OC-43